Table 3 Crude incident rates (number of events per 1000 patient years of risk) for all-cause mortality, cardiovascular mortality and commencement of renal replacement therapy according to baseline phosphate categories

<0.90 mmol/L

422

39

18.89

(10.94–32.46)

50.82

(34.87–66.77)

<0.001

0.90–1.09 mmol/L

912

96

21.90

(11.47–33.66)

54.38

(43.50–65.26)

Ref.

1.10–1.29 mmol/L

1004

130

21.68

(11.37–34.29)

67.48

(55.88–79.08)

<0.001

1.30–1.49 mmol/L

435

64

20.30

(11.63–32.23)

78.90

(59.57–98.23)

<0.001

≥1.50 mmol/L

177

46

17.58

(6.85–32.00)

154.94

(110.17–199.72)

<0.001

Total

2950

375

20.57

(11.14–33.48)

67.36

(60.54–74.18)

Phosphate categories

Number of Patients at risk

Number of Events

Crude Incidence Rate

95 % Confidence Interval

P value*

<0.90 mmol/L

422

6

18.89

(10.94–32.46)

7.82

(1.56–14.07)

0.003

0.90–1.09 mmol/L

912

18

21.90

(11.47–33.66)

10.20

(5.49–14.91)

Ref.

1.10–1.29 mmol/L

1004

24

21.68

(11.37–34.29)

12.46

(7.47–17.44)

0.037

1.30–1.49 mmol/L

435

6

20.30

(11.63–32.23)

7.40

(1.48–13.32)

<0.001

≥1.50 mmol/L

177

13

17.58

(6.85–32.00)

43.79

(19.98–67.59)

<0.001

Total

2950

67

20.57

(11.14–33.48)

12.03

(9.15–14.92)

Phosphate categories

Number of Patients at risk

Number of Events

Crude Incidence Rate

95 % Confidence Interval

P value*

<0.90 mmol/L

422

4

18.79

(10.93–32.36)

5.24

(0.10–10.38)

<0.001

0.90–1.09 mmol/L

912

14

21.65

(11.18–33.63)

8.00

(3.81–12.18)

Ref.

1.10–1.29 mmol/L

1004

21

20.91

(11.07–33.64)

11.05

(6.32–15.78)

0.004

1.30–1.49 mmol/L

435

26

19.42

(11.07–31.27)

33.26

(20.48–46.05)

<0.001

≥1.50 mmol/L

177

33

13.63

(4.78–28.09)

133.96

(88.25–179.67)

<0.001

Total

2950

98

19.88

(10.68–32.92)

18.01

(14.44–21.75)